These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 26057410)

  • 21. Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients.
    Firriolo FJ; Hupp WS
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Apr; 113(4):431-41. PubMed ID: 22668425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New oral anticoagulants for the prevention of stroke. Open questions in geriatric patients].
    Berthold HK
    Z Gerontol Geriatr; 2012 Aug; 45(6):498-504. PubMed ID: 22828994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How I treat target-specific oral anticoagulant-associated bleeding.
    Siegal DM; Garcia DA; Crowther MA
    Blood; 2014 Feb; 123(8):1152-8. PubMed ID: 24385535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.
    Baglin T; Keeling D; Kitchen S;
    Br J Haematol; 2012 Nov; 159(4):427-9. PubMed ID: 22970737
    [No Abstract]   [Full Text] [Related]  

  • 26. [New oral anticoagulants and digestive hemorrhages].
    Diallo I; Mallaret C; Jourdan S; Brardjanian S; Guisset M; Coton T
    Presse Med; 2014 Jan; 43(1):85-7. PubMed ID: 23706679
    [No Abstract]   [Full Text] [Related]  

  • 27. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications.
    Lazo-Langner A; Lang ES; Douketis J
    Crit Care; 2013 Jun; 17(3):230. PubMed ID: 23806169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute management of bleeding in patients on novel oral anticoagulants.
    Siegal DM; Crowther MA
    Eur Heart J; 2013 Feb; 34(7):489-498b. PubMed ID: 23220847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The laboratory and the direct oral anticoagulants.
    Tripodi A
    Blood; 2013 May; 121(20):4032-5. PubMed ID: 23564912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perioperative management of patients on new oral anticoagulants.
    Lai A; Davidson N; Galloway SW; Thachil J
    Br J Surg; 2014 Jun; 101(7):742-9. PubMed ID: 24777590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
    Spyropoulos AC; Douketis JD; Gerotziafas G; Kaatz S; Ortel TL; Schulman S;
    J Thromb Haemost; 2012 Apr; 10(4):692-4. PubMed ID: 22934291
    [No Abstract]   [Full Text] [Related]  

  • 33. New approaches to reversing oral anticoagulant therapy. Introduction.
    Nutescu EA
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S1-2. PubMed ID: 23640527
    [No Abstract]   [Full Text] [Related]  

  • 34. [Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013].
    Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P
    Ann Fr Anesth Reanim; 2013 Oct; 32(10):691-700. PubMed ID: 23993157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
    Fawole A; Daw HA; Crowther MA
    Cleve Clin J Med; 2013 Jul; 80(7):443-51. PubMed ID: 23821689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
    Chan KE; Edelman ER; Wenger JB; Thadhani RI; Maddux FW
    Circulation; 2015 Mar; 131(11):972-9. PubMed ID: 25595139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
    Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison.
    Loke YK; Pradhan S; Yeong JK; Kwok CS
    Br J Clin Pharmacol; 2014 Oct; 78(4):707-17. PubMed ID: 24617578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of the anti-F10a or anti-F2a generation action of rivaroxaban or dabigatran.
    Stief TW
    Blood Coagul Fibrinolysis; 2012 Oct; 23(7):619-21. PubMed ID: 22821003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New oral anticoagulant agents - general features and outcomes in subsets of patients.
    Schulman S
    Thromb Haemost; 2014 Apr; 111(4):575-82. PubMed ID: 24452881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.